{"id":"fec-t","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FEC (5-fluorouracil, epirubicin, cyclophosphamide) is a combination chemotherapy that damages DNA and inhibits cell division through multiple mechanisms. The subsequent taxane (docetaxel) stabilizes microtubules and prevents mitotic spindle formation. This sequential approach leverages different cytotoxic mechanisms to maximize tumor cell death in breast cancer.","oneSentence":"FEC→T is a sequential chemotherapy regimen combining fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel to kill rapidly dividing cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:27.478Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer (neoadjuvant or adjuvant treatment)"}]},"trialDetails":[{"nctId":"NCT00798070","phase":"PHASE3","title":"Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2007-02","conditions":"Breast Cancer","enrollment":2017},{"nctId":"NCT01996267","phase":"PHASE3","title":"Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2013-12","conditions":"Breast Cancer, HER2 Positive","enrollment":437},{"nctId":"NCT02659527","phase":"PHASE3","title":"PET/MRI in Patients With Suspected Prostate Cancer","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2016-01","conditions":"Prostate Cancer","enrollment":220},{"nctId":"NCT02897050","phase":"PHASE2","title":"Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer","status":"SUSPENDED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2016-09","conditions":"Breast Cancer","enrollment":170},{"nctId":"NCT00625898","phase":"PHASE3","title":"BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab","status":"TERMINATED","sponsor":"NSABP Foundation Inc","startDate":"2008-04","conditions":"Breast Cancer","enrollment":3509},{"nctId":"NCT01216111","phase":"PHASE3","title":"Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)","status":"COMPLETED","sponsor":"Fudan University","startDate":"2011-01-01","conditions":"Triple Negative Breast Cancer","enrollment":647},{"nctId":"NCT01501487","phase":"PHASE4","title":"MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I","status":"COMPLETED","sponsor":"Agendia","startDate":"2011-10","conditions":"Breast Cancer","enrollment":226},{"nctId":"NCT03349177","phase":"PHASE2, PHASE3","title":"Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Zhiyong Yu","startDate":"2017-11-27","conditions":"Breast Cancer, Pathological Complete Response, Neoadjuvant Chemotherapy","enrollment":200},{"nctId":"NCT01642771","phase":"PHASE3","title":"Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer","status":"UNKNOWN","sponsor":"China Breast Cancer Clinical Study Group","startDate":"2012-06","conditions":"Breast Cancer","enrollment":636},{"nctId":"NCT01824368","phase":"PHASE1, PHASE2","title":"Extracorporeal Photopheresis in Liver Transplantation. Phase II Clinical Trial in Safety and Efficacy in Patients With Gradual Decrease of Immunosuppression.","status":"COMPLETED","sponsor":"Red de Terapia Celular","startDate":"2013-04","conditions":"Liver Transplantation, Immunosuppression","enrollment":10},{"nctId":"NCT00976989","phase":"PHASE2","title":"A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-11","conditions":"Breast Cancer","enrollment":225},{"nctId":"NCT01159236","phase":"NA","title":"Molecular Triaging of Newly Diagnosed Breast Cancer","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-09","conditions":"Breast Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":187,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Epirubicin","Cyclophosphamide","Fluorouracil","Taxotere"],"phase":"phase_3","status":"active","brandName":"FEC→T","genericName":"FEC→T","companyName":"Karolinska University Hospital","companyId":"karolinska-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FEC→T is a sequential chemotherapy regimen combining fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel to kill rapidly dividing cancer cells. Used for Breast cancer (neoadjuvant or adjuvant treatment).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":5,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}